New oral drug cocktail shows promise for kids with resistant neuroblastoma
NCT ID NCT00093353
First seen May 12, 2026 · Last updated Jun 18, 2026 · Updated 6 times
Summary
This early-phase study tested a combination of three oral drugs (irinotecan, temozolomide, and cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to standard treatment. The goal was to find the safest dose of irinotecan when given with the other two drugs. Cefixime was included to help prevent diarrhea, a common side effect of irinotecan. The study focused on side effects and dosing, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, 30322, United States
-
Children's Hospital Boston
Boston, Massachusetts, 02115, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
-
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Memorial Hospital - Chicago
Chicago, Illinois, 60614, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289, United States
-
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, 94304, United States
-
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital
Houston, Texas, 77030-2399, United States
-
UCSF Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0718, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.